Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pembrolizumab and sunitinib malate work in treating
participants with thymic cancer that has spread to other places in the body or cannot be
removed by surgery and does not respond to treatment. Monoclonal antibodies, such as
pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Sunitinib
malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Giving pembrolizumab and sunitinib malate may work better in treating thymic cancer.